title: Evidence for maximal treatment of atherosclerosis: drastic reduction of cholesterol and fibrinogen restores vascular homeostasis.
abstract: This article summarizes the clinical and biochemical evidence for maximal treatment of atherosclerosis by a simultaneous 60% to 70% reduction of plasma low-density lipoprotein cholesterol (LDL cholesterol), fibrinogen, and lipoprotein a concentrations with heparin-mediated extracorporeal LDL/fibrinogen precipitation (HELP) apheresis and statins. Apheresis has proven efficient and safe in the treatment of more than 1,000 patients since 1984 and has been applied in children and adults for the treatment of homozygous and heterozygous familial hypercholesterolemia, coronary artery disease, ischemic cardiomyopathy, generalized atherosclerosis, or transplant-associated arteriosclerosis after cardiac transplantation. Simultaneous removal of the main atherogenic plasma compounds has an immediate impact on myocardial and peripheral vasomotion by increasing myocardial blood flow, coronary flow reserve, cerebral CO2-reactivity, and muscle oxygen tension. Removal of fibrinogen and cholesterol reduces plasma viscosity by 20% and erythrocyte aggregation by 60% which gives rise to applying the HELP apheresis in various microcirculatory disorders. Pilot studies on acute retinal ischemia, critical limb ischemia, and sudden hearing loss confirm this observation.
authors.affiliation: Institute of Clinical Chemistry, University Hospital Grosshadern, Ludwig Maximilians University München, Munich, Germany. Beate.Jaeger@klch.med.uni-muenchen.de
authors.forename: B R
authors.initials: BR
authors.lastname: Jaeger
mesh_terms: D000328:Adult; D001161:Arteriosclerosis / Q000097:blood* / Q000503:physiopathology / Q000628:therapy*; D001781:Blood Component Removal; D002648:Child; D008078:Cholesterol, LDL / Q000097:blood*; D004730:Endothelium, Vascular / Q000503:physiopathology*; D005112:Extracorporeal Circulation; D005340:Fibrinogen / Q000032:analysis*; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006493:Heparin / Q000627:therapeutic use; D006706:Homeostasis / Q000502:physiology*; D006801:Humans; D017270:Lipoprotein(a) / Q000097:blood
chemical_list: D008078:Cholesterol, LDL; D005343:Fibrinolytic Agents; D017270:Lipoprotein(a); D005340:Fibrinogen; D006493:Heparin